Type of information: Licensing agreement
Compound: combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor
Company: Trovagene (USA - CA) Massachusetts Institute of Technology (MIT) (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: androgen antagonist/Polo-like Kinase (PLK) inhibitor
- • On October 3, 2018, Trovagene announced that it has entered into an exclusive patent license agreement with the Massachusetts Institute of Technology (MIT). Under the agreement, Trovagene has exclusive rights to develop combination therapies that include anti-androgen or androgen antagonist and a Polo-like Kinase (PLK) inhibitor for the treatment of cancer. The exclusive license agreement is part of the company's strategy to explore the efficacy of onvansertib, its first-in-class, 3rd generation, highly-selective, oral PLK1 inhibitor, in combination with anti-androgen drugs in cancers including prostate, breast, pancreatic, lung and gastrointestinal.
- The discovery by Dr. Jesse Patterson, a post-doc in Dr. Yaffe's laboratory, and resulting patent, around the unique synergy between anti-androgen and PLK inhibitor combination therapies for inducing tumor cell death, may represent a new paradigm for using this combination of drugs across a number of cancer types. The combination therapies can be used to improve the initial efficacy of one or the other of the active agents, or to re-sensitize cells that have become resistant to one of the other active agents when administered alone.